FDA Approves Merck's KEYTRUDA® in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast Cancer Whose Tumors Express PD-L1 Pharmaceutical Investing
BioHarvest Sciences Inc. Appoints Nathaniel Averill as VP of Manufacturing, QA & Supply Chain Biotech Investing
Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD Biotech Investing
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference Biotech Investing
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
